{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:17:16Z","timestamp":1772713036220,"version":"3.50.1"},"reference-count":39,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Biomedical Laboratory Research and Development, VA Office of Research and Development","award":["#BX004127"],"award-info":[{"award-number":["#BX004127"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The phosphatidylinositol (PI3K)\/AKT\/mTOR axis represents an important therapeutic target to treat human cancers. A well-described downstream target of the PI3K pathway is the forkhead box O (FOXO) transcription factor family. FOXOs have been implicated in many cellular responses, including drug-induced resistance in cancer cells. However, FOXO-dependent acute phase resistance mediated by pictilisib, a potent small molecule PI3K inhibitor (PI3Ki), has not been studied. Here, we report that pictilisib-induced adaptive resistance is regulated by the FOXO-dependent rebound activity of receptor tyrosine kinases (RTKs) in mucinous colorectal adenocarcinoma (MCA) cells. The resistance mediated by PI3K inhibition involves the nuclear localization of FOXO and the altered expression of RTKs, including ErbB2, ErbB3, EphA7, EphA10, IR, and IGF-R1 in MCA cells. Further, in the presence of FOXO siRNA, the pictilisib-induced feedback activation of RTK regulators (pERK and pAKT) was altered in MCA cells. Interestingly, the combinational treatment of pictilisib (Pi3Ki) and FOXO1i (AS1842856) synergistically reduced MCA cell viability and increased apoptosis. These results demonstrate that pictilisib used as a single agent induces acute resistance, partly through FOXO1 inhibition. Therefore, overcoming PI3Ki single-agent adaptive resistance by rational design of FOXO1 and PI3K inhibitor combinations could significantly enhance the therapeutic efficacy of PI3K-targeting drugs in MCA cells.<\/jats:p>","DOI":"10.3390\/ijms241512331","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T11:04:38Z","timestamp":1690974278000},"page":"12331","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pictilisib-Induced Resistance Is Mediated through FOXO1-Dependent Activation of Receptor Tyrosine Kinases in Mucinous Colorectal Adenocarcinoma Cells"],"prefix":"10.3390","volume":"24","author":[{"given":"Murali R.","family":"Kuracha","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medicine, Omaha, NE 68198, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkatesh","family":"Govindarajan","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Creighton University School of Medicine, Omaha, NE 68178, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian W.","family":"Loggie","sequence":"additional","affiliation":[{"name":"Department of Surgery, Creighton University School of Medicine, Omaha, NE 68124, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Tobi","sequence":"additional","affiliation":[{"name":"Research and Development Service, Detroit VAMC, Detroit, MI 48201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7876-149X","authenticated-orcid":false,"given":"Benita L.","family":"McVicker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medicine, Omaha, NE 68198, USA"},{"name":"Research Service, Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5732\/cjc.012.10287","article-title":"Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy","volume":"32","author":"Tan","year":"2013","journal-title":"Chin. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase\u2013AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme in-hibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"ref_5","first-page":"33","article-title":"Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics","volume":"7","author":"Josephs","year":"2015","journal-title":"Transl. Oncogenomics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/00015458.2013.11680951","article-title":"Mucinous Differentiation in Colorectal Cancer: Molecular, Histological and Clinical Aspects","volume":"113","author":"Debunne","year":"2013","journal-title":"Acta Chir. Belg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/1097-0142(197604)37:4<1891::AID-CNCR2820370439>3.0.CO;2-Z","article-title":"Mucinous carcinoma of the colon and rectum","volume":"37","author":"Symonds","year":"1976","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.bjc.6604955","article-title":"Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and\/or irinotecan-based chemotherapy","volume":"100","author":"Catalano","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/annonc\/mdt591","article-title":"Metastatic pattern in colorectal cancer is strongly influenced by histological subtype","volume":"25","author":"Hugen","year":"2014","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejca.2011.12.004","article-title":"Mucinous adenocarcinomas: Poor prognosis in metastatic colorectal cancer","volume":"48","author":"Mekenkamp","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40880-019-0361-0","article-title":"Mucinous colorectal adenocarcinoma: Clinical pathology and treatment options","volume":"39","author":"Luo","year":"2019","journal-title":"Cancer Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cjp2.1","article-title":"The molecular background of mucinous carcinoma beyond MUC2","volume":"1","author":"Hugen","year":"2015","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kuracha, M.R., Thomas, P., Loggie, B.W., and Govindarajan, V. (2017). Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179510"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13058-018-1015-x","article-title":"A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer","volume":"20","author":"Cresta","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","article-title":"Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor","volume":"96","author":"Brunet","year":"1999","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/19328","article-title":"Direct control of the Forkhead transcription factor AFX by protein kinase B","volume":"398","author":"Kops","year":"1999","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9138","DOI":"10.1128\/MCB.20.24.9138-9148.2000","article-title":"Forkhead Transcription Factor FKHR-L1 Modulates Cytokine-Dependent Transcriptional Regulation of p27KIP1","volume":"20","author":"Dijkers","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"49795","DOI":"10.1074\/jbc.M309523200","article-title":"FoxO3a Transcriptional Regulation of Bim Controls Apoptosis in Paclitaxel-treated Breast Cancer Cell Lines","volume":"278","author":"Sunters","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.devcel.2018.02.014","article-title":"Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a Turnover","volume":"44","author":"Fitzwalter","year":"2018","journal-title":"Dev. Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature01036","article-title":"Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress","volume":"419","author":"Kops","year":"2002","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1126\/science.1101731","article-title":"Nutrient availability regulates SIRT1 through a forkhead-dependent pathway","volume":"306","author":"Nemoto","year":"2004","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1210\/me.2006-0118","article-title":"Differential Expression of FOXO1 and FOXO3a Confers Resistance to Oxidative Cell Death upon Endometrial Decidualization","volume":"20","author":"Kajihara","year":"2006","journal-title":"Mol. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.onc.1210626","article-title":"Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells","volume":"27","author":"Goto","year":"2007","journal-title":"Oncogene"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/carcin\/bgn092","article-title":"Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells","volume":"29","author":"Han","year":"2008","journal-title":"Carcinogenesis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00018-011-0900-6","article-title":"Eph-dependent cell-cell adhesion and segregation in development and cancer","volume":"69","author":"Nievergall","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/1541-7786.MCR-16-0176","article-title":"IGF-1 Receptor Modulates FoxO1-Mediated Tamoxifen Response in Breast Cancer Cells","volume":"15","author":"Zheng","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.semcancer.2019.07.003","article-title":"mTOR: Role in cancer, metastasis and drug resistance","volume":"59","author":"Murugan","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1535-7163.MCT-07-0397","article-title":"Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells","volume":"7","author":"Hui","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/s41374-019-0276-z","article-title":"Promotion of \u03b2-catenin\/Foxo1 signaling ameliorates renal interstitial fibrosis","volume":"99","author":"Rao","year":"2019","journal-title":"Lab. Investig."},{"key":"ref_31","first-page":"2464","article-title":"Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism","volume":"116","author":"Matsumoto","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/1476-4598-9-260","article-title":"Regulation of Erk1\/2 activation by osteopontin in PC3 human prostate cancer cells","volume":"9","author":"Robertson","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","article-title":"AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity","volume":"19","author":"Chandarlapaty","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/onc.2010.626","article-title":"PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer","volume":"30","author":"Serra","year":"2011","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"995","DOI":"10.15252\/embj.201695534","article-title":"AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction","volume":"36","author":"Pan","year":"2017","journal-title":"EMBO J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1074\/jbc.RA119.011571","article-title":"Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2\u2013mediated activation of forkhead box O1","volume":"295","author":"Xia","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1124\/mol.110.065714","article-title":"Discovery of Novel Forkhead Box O1 Inhibitors for Treating Type 2 Diabetes: Improvement of Fasting Glycemia in Diabetic db\/db Mice","volume":"78","author":"Nagashima","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/0008-5472.CAN-05-1997","article-title":"Paclitaxel-Induced Nuclear Translocation of FOXO3a in Breast Cancer Cells Is Mediated by c-Jun NH2-Terminal Kinase and Akt","volume":"66","author":"Sunters","year":"2006","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1158\/0008-5472.CAN-09-1504","article-title":"Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer","volume":"69","author":"Gan","year":"2009","journal-title":"Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/15\/12331\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:24:16Z","timestamp":1760127856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/15\/12331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":39,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["ijms241512331"],"URL":"https:\/\/doi.org\/10.3390\/ijms241512331","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]}}}